非表示:
キーワード:
GH-DEFICIENT ADULTS; HYPOPITUITARY CONTROL; REPLACEMENT THERAPY;
ENDOCRINE-SOCIETY; CARDIOVASCULAR RISK; PRACTICE GUIDELINE;
BODY-COMPOSITION; PRIMARY CANCERS; IGF-I; COMPLICATIONSEndocrinology & Metabolism; Obstetrics & Gynecology; Growth hormone deficiency; growth hormone dosing; growth hormone
therapy; insulin-like growth factor;
要旨:
We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509GH-treated patients (mean age: 48.9years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH dose increased more in females than males during treatment; this was statistically significant in years 2-6 (p<0.05). Over the 10-year study period, a time trend of an overall estimated GH dose increase by 0.06mg/day (females) and decrease by 0.07mg/day (males) was shown; this interaction of gender and calendar year was significant (p<0.0001). In both genders, overall GH dose decreased with increasing age (p<0.0001). Our study confirms that females and younger patients require higher GH doses compared with males and older patients.
